HOME >> BIOLOGY >> NEWS
Studies of rare blood syndrome yield novel route to cancer

By carefully studying why a rare blood disorder responds to the anti-cancer drug Gleevec, researchers have discovered an entirely new mechanism that generates cancer-causing genes.

The study, published in the March 27, 2003, issue of the New England Journal of Medicine, shows that Gleevec is an effective treatment for hypereosinophilic syndrome (HES), a blood disorder that is nearly always fatal. According to the researchers, their studies suggest that HES should be reclassified by the World Health Organization from its current "gray-area" status as a "syndrome" to a form of cancer.

Senior authors of the article were D. Gary Gilliland, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital and Harvard Medical School, and Richard Stone at the Dana-Farber Cancer Institute (DFCI). Joint first authors on the paper were Jan Cools, a postdoctoral fellow in Gilliland's laboratory, and Daniel DeAngelo, who is also at DFCI and an instructor at Harvard Medical School.

HES is caused by overproliferation of a type of white blood cells called eosinophils. Physicians treat the syndrome with a combination of drugs and chemotherapy, said Gilliland, but eventually, the assault of eosinophils damages major organs, and causes the heart or lungs to fail, and ultimately results in death of most patients.

Recently, however, hints that the disorder might respond to Gleevec began to crop up in the medical literature. "There was a report of a single case of an HES patient treated with Gleevec and had what was described as a miraculous response," said Gilliland. "This anecdotal report was substantiated by a group of investigators that reported successful treatment in 4 of 5 additional HES patients, reported in the The Lancet (a British medical journal) last year.

Gleevec works by inhibiting enzymes called tyrosine kinases. When the activity of
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
26-Mar-2003


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/25/2018)... ... 2018 , ... Researchers at the Icahn School of Medicine ... a long-standing computational concept known as “blacklisting,” which is commonly employed as a ... as a filter to single out genetic variations in patient genomes and exomes ...
(Date:12/19/2018)... ... December 19, 2018 , ... OrthoSpace Ltd. ... Arthroscopy evaluating the use of novel surgical techniques, including the OrthoSpace ... represent a painful, disabling condition for which there are historically few treatment options. ...
(Date:12/13/2018)... ... ... Study Protocol Summary of QC Procedure , 1 – Patient Enrolment (with ... the site., 3 - Three photos captured with Apple iPad and transferred to each ... Photos moved to eAdjudication® and submitted to Reviewers., 6 - Reviewers (blinded) repeats ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... ... ... adopted from a local shelter when he was around two years old. According to ... after he was adopted, he tore his right cruciate ligament. Though he had his ... a traumatic injury. , Sure enough, when Rascal was about nine years old, he began ...
(Date:1/8/2019)... ... 08, 2019 , ... The American Society of Gene and Cell Therapy’s ... selection committee made up of industry leaders identified by the ASGCT board of directors. ... awards created to support ASGCT members designing transformative pilot studies in gene and cell ...
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life ... cells in blood, has been named as a partner in Medigen Biotech’s upcoming ... cell therapies for cancer treatment, will use CellMax Life’s circulating tumor cell platform ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
Breaking Biology Technology:
Cached News: